Clinical and Metabolic Changes Following Adjunctive Intravenous Nanobubble-Based Gas Administration in Two Patients With Type 2 Diabetes Mellitus: A Case Report

Background: Type 2 diabetes mellitus (T2DM) is associated with metabolic dysregulation, endothelial dysfunction, and oxidative stress. Molecular hydrogen (H₂) and the endogenous gaseous signaling molecules nitric oxide (NO), hydrogen sulfide (H₂S), and carbon monoxide (CO) have attracted interest for their potential roles in vascular and redox homeostasis. Evidence concerning intravenous nanobubble-based administration of these gases in people with T2DM remains insufficient. Case presentation: Two male patients aged 59 and 74 years with T2DM and cardiometabolic comorbidities received adjunctive intravenous nanobubble-based gas administration. The first underwent approximately eight weeks of treatment; the second received 15 sessions over approximately 30 days. The clinical narrative reported selected laboratory measurements and subjective symptoms during follow-up. Clinical observations: Reported paired measurements included fasting glucose of 206 and 182 mg/dL and HbA1c of 8.5% and 7.6% before and after treatment; the source report did not unambiguously attribute these glycemic measurements to one patient. In the second patient, LDL cholesterol changed from 181 to 87 mg/dL, triglycerides from 250 to 186 mg/dL, and serum potassium from 6.3 to 4.6 mmol/L. Subjective symptom improvements and stable vital signs were described, and no adverse events were reported in the available narrative. Conclusion: The observed changes are descriptive and hypothesis-generating. This uncontrolled two-patient report cannot establish therapeutic efficacy, biological mechanisms, or safety. Further work requires standardized formulation characterization, safety evaluation, and controlled clinical studies.